{"id":4104,"date":"2026-02-25T08:25:46","date_gmt":"2026-02-25T07:25:46","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?page_id=4104"},"modified":"2026-02-25T08:25:46","modified_gmt":"2026-02-25T07:25:46","slug":"orphan-drugs","status":"publish","type":"page","link":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/","title":{"rendered":"Orphan Drugs"},"content":{"rendered":"\n<p>Une maladie est consid\u00e9r\u00e9e comme rare lorsqu&rsquo;elle touche moins de cinq personnes pour 10 000 habitants. \u00c9tant donn\u00e9 qu&rsquo;il existe entre 6 000 et 8 000 maladies rares r\u00e9pertori\u00e9es, l&rsquo;ensemble des maladies rares peut \u00eatre compar\u00e9 \u00e0 une maladie courante. Les entreprises pharmaceutiques du monde entier m\u00e8nent des recherches intensives pour mettre au point de nouveaux m\u00e9dicaments et traitements contre les maladies rares. En effet, malgr\u00e9 les progr\u00e8s consid\u00e9rables r\u00e9alis\u00e9s ces derni\u00e8res ann\u00e9es, de nombreuses maladies rares ne peuvent toujours pas \u00eatre trait\u00e9es.<\/p>\n\n\n\n<p>Les autorit\u00e9s ont mis en place des incitations pour le\nsecteur pharmaceutique dans le but d\u2019accro\u00eetre l\u2019attractivit\u00e9 de la recherche\net du d\u00e9veloppement de m\u00e9dicaments orphelins. D\u00e8s 1983, une loi est entr\u00e9e en\nvigueur aux \u00c9tats-Unis pour encourager le d\u00e9veloppement de m\u00e9dicaments contre\nles maladies rares. De m\u00eame, l\u2019UE a \u00e9tabli en 1999 une base juridique similaire\npar le R\u00e8glement 141\/2000. Elle a pris diverses mesures pour promouvoir la reconnaissance\net la visibilit\u00e9 des maladies rares et elle renforce la coop\u00e9ration et la\ncoordination \u00e0 l\u2019\u00e9chelle de l\u2019UE. Elle soutient la mise en place de r\u00e9seaux\neurop\u00e9ens de r\u00e9f\u00e9rence et encourage les liens entre les centres sp\u00e9cialis\u00e9s et\nles experts de diff\u00e9rents pays. Elle a aussi cr\u00e9\u00e9 des incitations \u00e0 la\nrecherche dans le domaine des maladies rares. De plus, les maladies rares sont\nl\u2019une des priorit\u00e9s du programme-cadre de l\u2019UE pour la recherche et le\nd\u00e9veloppement. Ces mesures d\u2019encouragement ont contribu\u00e9 \u00e0 faire augmenter le\nnombre de m\u00e9dicaments autoris\u00e9s contre des maladies rares. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medicaments-orphelins-en-suisse\"><strong>M\u00e9dicaments\norphelins en Suisse<\/strong><\/h2>\n\n\n\n<p>En Suisse, la loi sur les produits th\u00e9rapeutiques (LPTh,\nart. 14) pr\u00e9voit des proc\u00e9dures d\u2019autorisation de mise sur le march\u00e9 simplifi\u00e9es\npour les m\u00e9dicaments importants pour des maladies rares. Les dispositions\nd\u2019ex\u00e9cution \u00e0 ce sujet figurent dans l\u2019ordonnance de l\u2019Institut suisse des\nproduits th\u00e9rapeutiques sur l\u2019autorisation simplifi\u00e9e de m\u00e9dicaments et\nl\u2019autorisation de m\u00e9dicaments sur annonce (OASM\u00e9d) Celle-ci distingue la\nreconnaissance du statut de m\u00e9dicament important contre des maladies rares\n(art. 4 \u00e0 7 OASM\u00e9d) et l\u2019autorisation d\u2019un m\u00e9dicament dont le statut de\nm\u00e9dicament orphelin a d\u00e9j\u00e0 \u00e9t\u00e9 reconnu par Swissmedic (art. 24 \u00e0 26 OASM\u00e9d).<\/p>\n\n\n\n<p>Le remboursement des m\u00e9dicaments orphelins se fait soit\nconform\u00e9ment \u00e0 la liste des sp\u00e9cialit\u00e9s, soit selon l\u2019art.&nbsp;71b OAMal, dans\nles m\u00eames conditions qu\u2019en cas d\u2019utilisation hors \u00e9tiquette. Cet article permet\nla prise en charge des co\u00fbts d\u2019un m\u00e9dicament ne figurant pas dans la liste des\nsp\u00e9cialit\u00e9s et utilis\u00e9 pour une autre indication que celle mentionn\u00e9e dans la\nnotice. Mais ceci uniquement si la maladie est susceptible d\u2019\u00eatre mortelle pour\nl\u2019assur\u00e9-e ou de lui causer des probl\u00e8mes de sant\u00e9 graves et chroniques et\nqu\u2019il n\u2019existe pas d\u2019alternative th\u00e9rapeutique.<\/p>\n\n\n\n<p>Ce processus de d\u00e9cision est complexe et les patient-e-s\natteint-e-s de maladies rares sont souvent d\u00e9savantag\u00e9-e-s au niveau du\nremboursement par rapport aux patient-e-s souffrant de maladies plus\nfr\u00e9quentes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une maladie est consid\u00e9r\u00e9e comme rare lorsqu&rsquo;elle touche moins de cinq personnes pour 10 000 habitants. \u00c9tant donn\u00e9 qu&rsquo;il existe entre 6 000 et 8 000 maladies rares r\u00e9pertori\u00e9es, l&rsquo;ensemble des maladies rares peut \u00eatre compar\u00e9 \u00e0 une maladie courante. Les entreprises pharmaceutiques du monde entier m\u00e8nent des recherches intensives pour mettre au point de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":4140,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-4104","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Orphan Drugs - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orphan Drugs\" \/>\n<meta property=\"og:description\" content=\"Une maladie est consid\u00e9r\u00e9e comme rare lorsqu&rsquo;elle touche moins de cinq personnes pour 10 000 habitants. \u00c9tant donn\u00e9 qu&rsquo;il existe entre 6 000 et 8 000 maladies rares r\u00e9pertori\u00e9es, l&rsquo;ensemble des maladies rares peut \u00eatre compar\u00e9 \u00e0 une maladie courante. Les entreprises pharmaceutiques du monde entier m\u00e8nent des recherches intensives pour mettre au point de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/\",\"name\":\"Orphan Drugs - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"datePublished\":\"2026-02-25T07:25:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nos th\u00e8mes\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/themen\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Le patient au centre des consid\u00e9rations\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Acc\u00e8s des patient-e-s\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Orphan Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Orphan Drugs - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/","og_locale":"fr_FR","og_type":"article","og_title":"Orphan Drugs","og_description":"Une maladie est consid\u00e9r\u00e9e comme rare lorsqu&rsquo;elle touche moins de cinq personnes pour 10 000 habitants. \u00c9tant donn\u00e9 qu&rsquo;il existe entre 6 000 et 8 000 maladies rares r\u00e9pertori\u00e9es, l&rsquo;ensemble des maladies rares peut \u00eatre compar\u00e9 \u00e0 une maladie courante. Les entreprises pharmaceutiques du monde entier m\u00e8nent des recherches intensives pour mettre au point de [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/","og_site_name":"Interpharma","twitter_card":"summary_large_image","twitter_site":"@interpharma_ch","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/","url":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/","name":"Orphan Drugs - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"datePublished":"2026-02-25T07:25:46+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/orphan-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Nos th\u00e8mes","item":"https:\/\/www.interpharma.ch\/fr\/themen\/"},{"@type":"ListItem","position":3,"name":"Le patient au centre des consid\u00e9rations","item":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/"},{"@type":"ListItem","position":4,"name":"Acc\u00e8s des patient-e-s","item":"https:\/\/www.interpharma.ch\/fr\/themen\/der-patient-im-mittelpunkt\/acces-des-patient-e-s\/"},{"@type":"ListItem","position":5,"name":"Orphan Drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/4104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=4104"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/4104\/revisions"}],"predecessor-version":[{"id":4105,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/4104\/revisions\/4105"}],"up":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/4140"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=4104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}